Xeris Pharmaceuticals, a late-stage pharma commercializing an injectable hypoglycemia treatment, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.
The Chicago, IL-based company was founded in 2005 and booked $1 million in revenue for the 12 months ended March 31, 2018. It plans to list on the Nasdaq under the symbol XERS. Jefferies, Leerink Partners and RBC Capital Markets are the joint bookrunners on the deal. No pricing terms were disclosed.
